Welcome to our dedicated page for Roivant Sciences SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Roivant Sciences Ltd. (Nasdaq: ROIV) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Bermuda-incorporated biopharmaceutical issuer with common shares listed on The Nasdaq Global Select Market, Roivant files annual reports, quarterly updates, current reports on Form 8-K, proxy statements and other disclosures that describe its business, governance, financial condition and material events.
Through Roivant’s filings, investors can review detailed information on its biopharmaceutical pipeline, including brepocitinib, IMVT-1402, batoclimab and mosliciguat, as well as the activities of subsidiaries such as Priovant Therapeutics, Immunovant, Pulmovant and Genevant. Current reports on Form 8-K have been used to furnish press releases on quarterly financial results, to report positive Phase 3 VALOR data in dermatomyositis, to provide updates on Graves’ disease development at Immunovant, and to disclose authorization of common share repurchase programs.
Roivant’s periodic reports discuss consolidated research and development and general and administrative expenses, share-based compensation, gains and losses from transactions such as the sale of Telavant net assets and the sale of its equity interest in Dermavant, and income or loss from discontinued operations. The company’s definitive proxy statement on Schedule 14A describes its annual general meeting of shareholders, director elections, auditor ratification and advisory votes on executive compensation, and lays out governance and compensation policies.
On Stock Titan, Roivant filings are paired with AI-powered summaries designed to help readers interpret complex documents. Users can quickly see the key points from 10-K and 10-Q reports, understand the significance of 8-K disclosures, and locate information related to capital allocation, clinical programs and subsidiary activities. Form 4 and other ownership-related filings, when available, can be used to track insider transactions and equity incentives disclosed by the company.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker exercised stock options for 200,000 Common Shares at an exercise price of $3.85 per share and on the same day sold 200,000 Common Shares in open-market transactions at a weighted average price of $28.24 per share.
Following these transactions, Venker directly owned 1,647,546 Common Shares. The sale price reflects multiple trades within a range from $28.04 to $28.45, as disclosed in the filing footnotes.
Roivant Sciences Ltd. director Melissa B. Epperly reported an open-market sale of 41,861 common shares on March 16, 2026 at a weighted average price of $28.68 per share. The shares were sold in multiple trades priced between $28.50 and $28.84. After this transaction, she directly holds 15,804 common shares of Roivant Sciences.
Rockefeller Financial LLC filed a Form 144 notice to sell 200,000 Common Shares of Roivant Sciences Ltd. The sale is described as resulting from an options exercise with grant date 04/20/2022 and the proposed transaction date 03/17/2026, with proceeds to be transmitted by wire.
The excerpt also lists recent sales by Eric Venker, including multiple transactions of 200,000 shares on 02/13/2026 and 01/12/2026 and smaller tranches on other dates; these prior sales are shown with corresponding gross amounts in the table.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice for ROIV reporting restricted stock vesting events under a registered plan. The filing lists multiple vesting dates and per‑event share counts, including 13,580 shares vesting on 09/12/2024 and 14,745 shares vesting on 09/10/2025.
The entries are described as "Restricted stock vesting under a registered plan" with the issuer listed as the source of the vested shares. The filing documents the timing and share amounts of these compensation‑related vesting events rather than open‑market trades.
Roivant Sciences Ltd ownership filing: an amendment to a Schedule 13G/A reports that FMR LLC beneficially owns 73,641,253.25 shares of Roivant common stock, equal to 10.3% of the class. The filing states FMR LLC has sole dispositive power over 73,641,253.25 shares and shared voting power of 0.00. The cover also lists Abigail P. Johnson with sole dispositive power of 73,641,253.25 shares and a 10.3% ownership figure. The filing includes Item 6 disclosure that other persons may have rights to dividends or sale proceeds, and references an Exhibit 99 agreement and powers of attorney; signatures are dated 03/05/2026.
Roivant Sciences reported that its subsidiary Genevant Sciences and partner Arbutus Biopharma entered into a $2.25 billion global settlement with Moderna to resolve all U.S. and international patent disputes over lipid nanoparticle technology used in COVID-19 vaccines, including Spikevax.
Under the settlement, Moderna will pay Genevant/Arbutus a $950 million noncontingent lump sum on or before July 8, 2026, plus a potential $1.3 billion contingent lump sum depending on the outcome of an appeal relating to 28 U.S.C. § 1498, with possible prorating and repayment mechanics if later overturned. The agreement also grants Moderna a fully paid-up, royalty-free, irrevocable, non-exclusive worldwide license and covenants not to sue for specified vaccines and patents.
Roivant’s board also expanded its common share repurchase program to up to $1.0 billion, inclusive of a previously announced $500 million authorization. Repurchases, funded from cash and cash equivalents, may occur via tender offers, open-market purchases, or privately negotiated transactions and can be suspended or discontinued at any time.
Roivant Sciences, through its subsidiary Priovant Therapeutics, announced that the FDA has accepted the New Drug Application for brepocitinib to treat dermatomyositis and granted it Priority Review. The FDA set a PDUFA target action date in the third quarter of 2026, and the company expects a U.S. launch at the end of September 2026 if approved.
The Priority Review decision is based on positive Phase 3 VALOR data in 241 patients, where the 30 mg dose showed statistically significant and clinically meaningful improvement over placebo on the primary Total Improvement Score endpoint at Week 52 and all nine key secondary endpoints. Safety data across more than 2,000 subjects suggest a profile similar to approved JAK and TYK2 inhibitors, although serious infections were more frequent with the 30 mg dose and required medical management.
Roivant Sciences Ltd. reported that CFO Richard Pulik had 1,000 common shares withheld at a price of $27.15 per share to cover tax obligations from the vesting of previously granted RSUs. After this tax-withholding disposition, he directly holds 238,413 common shares.
Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported a Form 4 showing a tax-related share disposition. On this date, 7,051 common shares were withheld and net-settled by the company to satisfy tax withholding obligations arising from the vesting of previously granted RSUs. After this tax-withholding disposition, Venker directly owned 1,647,546 common shares.
Roivant Sciences Ltd. President and Vant Chair Frank Torti reported a series of stock option exercises and related share sales. Between February 19 and 23, he exercised options to acquire a total of 3,000,000 Common Shares at an exercise price of $3.85 per share and then sold the same number of shares in open-market transactions.
The sales covered 1,400,000, 1,012,610, and 587,390 Common Shares at weighted average prices of $27.42, $27.15, and $27.51 per share, respectively, with individual trades occurring between $26.70 and $27.80. After these transactions, Torti directly owned 13,736,547 Common Shares and held 3,026,184 stock options.